The CEO+CFO simultaneous open-market sales without a 10b5-1 plan or disclosed catalyst is a cautionary signal for a high-valuation biotech. Monitor for upcoming pipeline data readouts or clinical trial updates that may have prompted insider selling. The 95% analyst bullish consensus creates downside risk if insiders are proven correct.
RLAY drugs
RLAY drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 19 $20.74entry
- T+1 · 3mo ago −5.01%α −4.17% · $19.70
- T+5 · 3mo ago −6.17%α −5.78% · $19.46
- T+20 · 2mo ago −7.47%α −6.63% · $19.19
- T+60 · 5d ago −4.92%α −4.09% · $19.72
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Relay Therapeutics' CEO and CFO sold a combined $1.33M in open-market sales over a 4-day window, representing ~0.03% of the $4.5B market cap. While the dollar amount is trivial relative to company size, the cluster involves both the CEO and CFO selling simultaneously, which is notable for a biotech with a $4.5B market cap and 95% analyst bullishness. The sales are not part of a 10b5-1 plan pattern and occur without any disclosed negative catalyst, suggesting potential insider caution ahead of upcoming pipeline data or earnings.
Key Financial Metrics
Key Facts
- CEO Sanjiv Patel sold 48,199 shares for $979,886 on 2026-08-17
- CFO Thomas Catinazzo sold 17,717 shares for $349,734 on 2026-08-14
- Total insider sales of $1.33M represent ~0.03% of $4.5B market cap
- Both sales are open-market (code S), not 10b5-1 plan or tax withholding
- No recent positive catalyst or earnings release to explain selling
- 95% of analysts rate the stock Buy/Strong Buy
Financial Impact
Insider sales of $1.33M, trivial relative to $4.5B market cap (0.03%)
Risk Factors
- Insider sales may signal management's lack of confidence in near-term pipeline catalysts
- High analyst bullishness (95% Buy/Strong Buy) creates asymmetric downside if sentiment shifts
- No disclosed negative catalyst, selling could be diversification but timing is suspicious
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RLAY-1787121416661 |
Track record
21 reports on RLAY
5 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +65.12% at T+60 after the May 19, 2026 report. 7 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $17.68 Now $17.27 −2.29% settles Feb 12
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $17.00 Now $17.27 +1.59% settles Feb 3
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $17.44 Now $17.27 −0.97% settles Feb 1
- Oct 7, 20265w ago 144 Neutral 2/10 Entry $17.41 Now $17.27 −0.80% settles Jan 5
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $17.95 Now $17.27 −3.79% settles Jan 4
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $18.89 Now $17.27 −8.58% settles Dec 4
- Aug 28, 202611w ago Insider Cluster Bearish 6/10 Entry $18.77 Now $17.27 +7.99% settles Nov 23
- Aug 18, 202612w ago Insider Cluster Bearish 5/10 Viewing Entry $20.74 to $19.72 Now $17.27 +16.73% ▲ +4.92% +4.09% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers